Andrew S. Brohl

5.5k total citations
100 papers, 2.0k citations indexed

About

Andrew S. Brohl is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Andrew S. Brohl has authored 100 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Andrew S. Brohl's work include Polyomavirus and related diseases (22 papers), Sarcoma Diagnosis and Treatment (19 papers) and CAR-T cell therapy research (17 papers). Andrew S. Brohl is often cited by papers focused on Polyomavirus and related diseases (22 papers), Sarcoma Diagnosis and Treatment (19 papers) and CAR-T cell therapy research (17 papers). Andrew S. Brohl collaborates with scholars based in United States, France and Italy. Andrew S. Brohl's co-authors include Damon R. Reed, Goodwin G. Jinesh, Zeynep Eroglu, Jamie K. Teer, Sean Yoder, Elliot Kahen, Georgina V. Long, Kristin Kathleen Ancell, Allison Betof Warner and Douglas B. Johnson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Andrew S. Brohl

91 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew S. Brohl United States	22	1.2k	528	426	346	291	100	2.0k
Jean-Marie Cuillerot United States	7	1.6k 1.3×	325 0.6×	226 0.5×	556 1.6×	309 1.1×	10	1.8k
Aleodor A. Andea United States	25	1.8k 1.4×	337 0.6×	562 1.3×	122 0.4×	221 0.8×	94	2.7k
Mattheos Bobos Greece	23	1.1k 0.9×	487 0.9×	620 1.5×	72 0.2×	113 0.4×	103	1.9k
Glenn J. Hanna United States	26	1.4k 1.1×	582 1.1×	591 1.4×	309 0.9×	94 0.3×	149	2.6k
O. Hans Iwenofu United States	21	502 0.4×	410 0.8×	618 1.5×	206 0.6×	58 0.2×	80	1.5k
B. Llombart Spain	24	1.2k 1.0×	735 1.4×	231 0.5×	53 0.2×	179 0.6×	138	2.1k
Angela Hong Australia	32	1.8k 1.4×	1.0k 2.0×	767 1.8×	269 0.8×	46 0.2×	155	3.2k
Franz O. Smith United States	12	2.1k 1.6×	282 0.5×	491 1.2×	1.4k 4.0×	119 0.4×	20	2.4k
Luigi Chiusa Italy	28	805 0.6×	331 0.6×	594 1.4×	287 0.8×	43 0.1×	76	2.3k
Jose A. Plaza United States	27	823 0.7×	459 0.9×	318 0.7×	211 0.6×	43 0.1×	107	2.1k

Countries citing papers authored by Andrew S. Brohl

Since Specialization

Citations

This map shows the geographic impact of Andrew S. Brohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew S. Brohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew S. Brohl more than expected).

Fields of papers citing papers by Andrew S. Brohl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew S. Brohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew S. Brohl. The network helps show where Andrew S. Brohl may publish in the future.

Co-authorship network of co-authors of Andrew S. Brohl

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew S. Brohl. A scholar is included among the top collaborators of Andrew S. Brohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew S. Brohl. Andrew S. Brohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khushalani, Nikhil I., Ghassan El‐Haddad, Kenneth L. Gage, et al.. (2024). First-in-human study of ²²⁵actinium mti-201 (²²⁵Ac-MTI-201) in metastatic uveal melanoma (UM).. Journal of Clinical Oncology. 42(16_suppl). TPS9612–TPS9612. 1 indexed citations

Khushalani, Nikhil I., Ghassan El‐Haddad, Kenneth L. Gage, et al.. (2024). 1128P Preliminary results of first-in-human study of 225-Actinium MTI-201 (225Ac-MTI-201) in metastatic uveal melanoma. Annals of Oncology. 35. S742–S742. 1 indexed citations

Brohl, Andrew S., Ann W. Silk, Jacob Thomas, et al.. (2024). Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology. 42(16_suppl). 9592–9592. 1 indexed citations

Eroglu, Zeynep, Joseph Markowitz, Lilit Karapetyan, et al.. (2024). Durability of immune checkpoint inhibitor (ICI) response following treatment discontinuation in advanced merkel cell carcinoma (MCC).. Journal of Clinical Oncology. 42(16_suppl). 9596–9596.

D’Angelo, Sandra P., et al.. (2024). Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma. Clinical Cancer Research. 30(19). 4352–4362. 8 indexed citations

Markowitz, Joseph, Michael J. Shamblott, Andrew S. Brohl, et al.. (2024). First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0. Molecular Cancer Therapeutics. 23(8). 1139–1143. 5 indexed citations

Eroglu, Zeynep, Joseph Markowitz, Lilit Karapetyan, et al.. (2024). Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma. Journal for ImmunoTherapy of Cancer. 12(9). e009816–e009816. 5 indexed citations

Hoogland, Aasha I., Andrew S. Brohl, Brent J. Small, et al.. (2024). Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy. Cancer Medicine. 13(14). e7464–e7464. 2 indexed citations

Jinesh, Goodwin G., Marco Napoli, Zheng‐Xiang Li, et al.. (2023). C19MC miRNA-520G induces SP100 antiviral gene transcription and inhibits melanin production in skin cutaneous melanoma. Genes & Diseases. 11(1). 60–63. 3 indexed citations

10.

Brohl, Andrew S., Joseph Markowitz, Zeynep Eroglu, et al.. (2023). Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma.. Journal of Clinical Oncology. 41(16_suppl). 9534–9534. 6 indexed citations

11.

Marin‐Acevedo, Julian A., Youngchul Kim, Andrew S. Brohl, et al.. (2023). Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. Cancers. 15(12). 3180–3180. 14 indexed citations

12.

Eroglu, Zeynep, Y. Ann Chen, Inna Smalley, et al.. (2023). Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma. Cancer. 130(2). 232–243. 9 indexed citations

13.

D’Angelo, Sandra P., Célèste Lebbé, Laurent Mortier, et al.. (2021). First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. Journal for ImmunoTherapy of Cancer. 9(7). e002646–e002646. 80 indexed citations

14.

Martín‐Broto, Javier, Antonio López–Pousa, Andrew S. Brohl, et al.. (2020). Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Molecular Cancer Therapeutics. 20(1). 132–141. 9 indexed citations

15.

Setty, Bhuvana A., Goodwin G. Jinesh, Michael Arnold, et al.. (2020). The genomic landscape of undifferentiated embryonal sarcoma of the liver is typified by C19MC structural rearrangement and overexpression combined with TP53 mutation or loss. PLoS Genetics. 16(4). e1008642–e1008642. 25 indexed citations

16.

Diab, Adi, Brendan D. Curti, Mehmet Asım Bilen, et al.. (2020). 368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors. SHILAP Revista de lepidopterología. A224.2–A225. 11 indexed citations

17.

Knepper, Todd C., Meagan Montesion, Jeffery S. Russell, et al.. (2019). The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research. 25(19). 5961–5971. 111 indexed citations

18.

Bridge, Julia A., János Sümegi, Mihaela Druta, et al.. (2019). Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. Modern Pathology. 32(11). 1593–1604. 65 indexed citations

19.

Jinesh, Goodwin G., Elsa R. Flores, & Andrew S. Brohl. (2018). Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers. PLoS ONE. 13(10). e0206008–e0206008. 38 indexed citations

20.

Brohl, Andrew S., et al.. (2018). Checkpoint inhibitor–associated cutaneous small vessel vasculitis. JAAD Case Reports. 4(7). 675–677. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact